Euthymics expands series A financing to work on 'next generation Straterra'
This article was originally published in Scrip
Euthymics Bioscience has added $4 million to its series A financing to fund preclinical development of its second product candidate, EB-1020, a non-stimulant for adult attention deficit hyperactivity disorder (ADHD). The product is "a different drug altogether" from Shire's non-stimulant ADHD drug Intuniv (guanfacine), Euthymic's president and CEO, Anthony McKinney, told Scrip.
You may also be interested in...
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.